At the beginning of this month of June, the Food and Drug Administration (FDA) announced its decision to grant marketing authorisation to the monoclonal antibody aducanumab, the first treatment option ...

Lecanemab Favors Early Aggregates. Fluorescently labeled lecanemab (green) bound most strongly to soluble Aβ aggregates ...

The drugs, aducanumab (Aduhelm) and lecanemab (Leqembi), were approved in June 2021 and January 2023, respectively. Both drugs were developed by pharmaceutical companies Biogen and Eisai, and they ...

Aducanumab does not appear to be effective at treating adults with early-stage symptoms, the EMA said. Alzheimer's charities say they are disappointed by the decision because thousands of people ...

Aducanumab targets the underlying cause of Alzheimer's, the most common form of dementia, rather than its symptoms. Charities have welcomed the news of a new therapy for the condition. But ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum ...

The Alzheimer's Association says more than 122,000 Missourians 65 years and older are battling Alzheimer's Disease, which has ...

New treatments for Alzheimer disease don’t reverse cognitive symptoms, but they do significantly slow progression. Evidence suggests that earlier treatment is most effective.

Copyright: © 2020 The Author(s). Published by Elsevier B.V. In March, 2019, Biogen announced its decision to halt further research on its amyloid-targeting antibody ...

In the past 20 years, only two medications have been approved which only treat symptoms. Recently, Aducanumab is the first FDA-approved anti-amyloid drug designed to affect disease progression but it ...